PHILADELPHIA, Oct. 27, 2008 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) said that its collaborator, Advanced Immune Therapeutics ("AIT") (Wellesley, MA), will present new data on Ampligen(r) (Poly I: Poly C12U), an experimental immunotherapeutic, at the iSBTc annual conference in San Diego, CA, Oct. 31, 2008. The mission of the International Society for Biological Therapy of Cancer (iSBTc) is to "facilitate exchange of the most cutting edge preclinical and clinical data on the use of biological therapies in cancer."
